BRAF and B-cell chronic lymphocytic leukemia: In CLL, sorafenib, a multikinase inhibitor, induces cell death independently of BRAF status, whereas incubation of BRAF mutated CLL cells with PLX4720, the vemurafenib progenitor [96], vemurafenib or dabrafenib [95] fails to induce cytotoxicity probably because these BRAF inhibitors are specific for V600 mutation, and this specific mutation is rare in CLL.